Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Artificial Intelligence in Cancer Diagnostics Market Size & Share 2026-2035
Report ID: GMI13802
|
Published Date: November 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Artificial Intelligence in Cancer Diagnostics Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Artificial Intelligence in Cancer Diagnostics Market Size
The artificial intelligence in cancer diagnostics market was valued at USD 380 million in 2025, is expected to reach USD 486 million in 2026, and is projected to grow at 24% CAGR from 2026 to 2035, reaching USD 3.29 billion by 2035.
Artificial Intelligence in Cancer Diagnostics Market Key Takeaways
Market Leader: GE HealthCare led with over 20.0% market share in 2025.
The artificial intelligence in cancer diagnostics market is moving from isolated clinical pilots toward enterprise deployment across imaging, pathology, endoscopy, and molecular-analysis workflows. Recurring software, implementation, and model-management contracts are becoming more consequential as providers seek platforms that fit existing clinical systems rather than stand-alone diagnostic tools.
GMI Analyst View
Our primary research engagements with oncology imaging procurement leads indicate that the artificial intelligence in cancer diagnostics market generated USD 312 million in 2024, reflecting a sharp acceleration in AI contract activity as clinical validation evidence reached decision-making thresholds for hospital procurement committees across multiple care settings.
Artificial Intelligence in Cancer Diagnostics Market Trends, Growth Drivers & GMI Forecast Outlook
Cancer-screening demand, diagnostic workforce constraints, regulatory progress, and enterprise workflow integration are jointly widening the practical use cases for AI. Growth will depend not only on algorithmic performance, but also on vendors' ability to satisfy hospital security, interoperability, and implementation requirements.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Cancer incidence is a structural source of diagnostic workload rather than a short-cycle demand variable. Rising caseloads place radiology, pathology, and screening programs under pressure to identify high-priority findings quickly while preserving specialist review for complex cases. AI-enabled triage, computer-aided detection, and digital slide analysis can help redistribute that workload by flagging suspicious studies and reducing manual review of lower-risk cases.
Regulatory momentum is also changing procurement behavior. A deeper base of cleared AI-enabled devices gives health-system committees more reference points for clinical validation, governance review, and vendor diligence. That shift favors suppliers able to translate clearance history into reproducible deployment pathways across imaging and laboratory settings.
Interoperability has become a commercial requirement rather than a technical add-on. Providers increasingly evaluate whether AI outputs can flow into established imaging, laboratory, and clinical-reporting workflows without creating duplicate work. Vendors with deployable integrations and disciplined implementation capabilities are therefore positioned to convert clinical interest into broader enterprise contracts.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Security scrutiny can lengthen the period between clinical evaluation and contract execution. AI diagnostic deployments often require providers to assess data access, de-identification practices, cloud architecture, retention policies, and incident-response obligations across highly sensitive imaging, pathology, and patient-record environments. Suppliers that can substantiate governance controls are better placed to reduce friction in risk-sensitive procurement settings.
Cybersecurity pressure also reallocates hospital technology budgets. When provider organizations must prioritize defensive infrastructure and operational resilience, discretionary investment in new clinical platforms can be delayed even where the clinical case is strong. This makes security certification, transparent vendor oversight, and compatibility with existing security operations central to commercial credibility.
Legacy infrastructure creates a separate constraint. Heterogeneous PACS, RIS, LIS, and interface environments can require custom configuration, testing, and workflow redesign before an AI tool reaches routine clinical use. Cloud-hosted offerings with established connectors can moderate that burden, but infrastructure variability will remain a material barrier among smaller and resource-constrained providers.
GMI Analyst View
We see the market's next competitive phase being defined less by isolated algorithm claims and more by the ability to navigate institutional buying requirements. Vendors that combine regulatory depth, integration discipline, and credible data-governance practices should have a clearer route to enterprise adoption than point solutions that add workflow complexity.
Artificial Intelligence in Cancer Diagnostics Market Segment Analysis
By Component
Software solutions generated USD 258 million in 2025 and are expected to reach USD 2.30 billion by 2035. The artificial intelligence in cancer diagnostics market increasingly favors software-led platforms because recurring licensing, continuous model updates, and compatibility with hospital information systems allow vendors to expand within an account after initial clinical adoption.
Hardware accounted for a 17% revenue share in 2025 and is projected to grow at 22.6% CAGR from 2026 to 2035. Demand remains tied to AI-enabled imaging systems, where embedded processing can improve image acquisition, support lesion detection, and strengthen workflow efficiency when providers replace aging diagnostic equipment.
Services represented a 15% revenue share in 2025 and are expected to reach USD 497 million by 2035. Implementation, workflow configuration, clinician training, and model-management requirements make services commercially important as health systems move from pilot installations to multi-site deployments.
By Cancer Type
Breast cancer generated USD 95 million in 2025 and is expected to reach USD 724 million by 2035. Its position reflects established mammography infrastructure, extensive clinical validation, and the need for scalable screening workflows that can support earlier detection while managing reading capacity.
Lung cancer accounted for a 22% revenue share in 2025 and is projected to grow at 24.0% CAGR from 2026 to 2035. Expansion of low-dose CT screening programs and the need to assess large volumes of nodules are reinforcing demand for AI that supports consistent triage and risk assessment.
Colorectal cancer generated USD 57 million in 2025 and is expected to reach USD 460 million by 2035. AI-assisted colonoscopy and pathology applications address high-throughput settings where detection consistency and timely review of biopsy material can affect care pathways.
Prostate cancer represented a 12% revenue share in 2025 and is expected to reach USD 395 million by 2035. MRI analysis and digital pathology applications are gaining relevance where providers seek more consistent interpretation of complex imaging and grading workflows.
Skin cancer generated USD 38 million in 2025 and is projected to grow at 26.1% CAGR from 2026 to 2035. Connected dermatoscopy, whole-body imaging, and telemedicine-compatible workflows can extend AI-supported assessment beyond specialist centers, giving this segment a distinct route to adoption.
Other cancers accounted for a 16% revenue share in 2025 and are expected to reach USD 594 million by 2035. Liquid biopsy analytics, AI-assisted endoscopy, and multimodal diagnostic platforms are broadening the addressable workflow base beyond imaging-centered applications.
By End Use
Hospitals generated USD 198 million in 2025 and are expected to reach USD 1.64 billion by 2035. Their concentration of high-acuity cancer care, imaging assets, pathology services, and enterprise IT resources makes them the principal setting for broad AI diagnostic deployments.
Diagnostic laboratories accounted for a 28% revenue share in 2025 and are projected to grow at 25.0% CAGR from 2026 to 2035. High specimen volumes make workflow automation, digital pathology, and genomic-analysis capabilities particularly relevant where laboratories can measure operational gains across repeated diagnostic processes.
Research & academic institutes generated USD 49 million in 2025 and are expected to reach USD 395 million by 2035. These institutions remain important validation partners, providing clinical datasets and translational research environments that can establish evidence before wider provider adoption.
Other end users represented a 7% revenue share in 2025 and are expected to reach USD 264 million by 2035. Screening programs, specialty clinics, and digital-health operators can extend AI-enabled diagnostics into decentralized care settings where traditional hospital-based infrastructure is less accessible.
GMI Analyst View
We believe segment expansion will increasingly reward platforms that can serve adjacent clinical workflows rather than a single diagnostic task. The commercial advantage is shifting toward suppliers that can connect imaging, pathology, molecular information, and implementation support into a coherent provider experience while preserving specialty-level clinical utility.
Artificial Intelligence in Cancer Diagnostics Market Regional Analysis
North America Artificial Intelligence in Cancer Diagnostics Market Analysis
North America generated USD 171 million in 2025 and is expected to reach USD 1.43 billion by 2035. The artificial intelligence in cancer diagnostics market benefits in the region from a mature health-IT base, a defined medical-device regulatory environment, large oncology networks, and significant demand for solutions that can improve diagnostic throughput.
U.S.
The U.S. generated USD 152 million in 2025 and is expected to reach USD 1.27 billion by 2035. Enterprise procurement by hospital networks, expanding digital pathology use, and integration of AI decision support into clinical systems underpin the country's central role in the regional market.
Canada
Canada accounted for a 5% revenue share in 2025 and is projected to grow at 22.6% CAGR from 2026 to 2035. Provincial health systems and organized screening programs provide an important adoption channel, although procurement remains shaped by public-sector budgeting and local implementation requirements.
Europe Artificial Intelligence in Cancer Diagnostics Market Analysis
Europe accounted for a 25% revenue share in 2025 and is expected to reach USD 753 million by 2035. The region's opportunity is supported by national cancer plans and digital-health investment, while regulatory expectations for transparency, performance, and clinical safety can raise the threshold for commercial deployment.
Germany
Germany generated USD 20 million in 2025 and is expected to reach USD 158 million by 2035. Its hospital infrastructure, specialist clinical base, and digital-health environment support adoption of imaging and pathology AI, particularly among academic and larger regional providers.
UK
The UK accounted for a 4.5% revenue share in 2025 and is expected to reach USD 135 million by 2035. National health-system initiatives focused on earlier cancer diagnosis create a pathway for population-scale evaluation and deployment of AI-supported screening tools.
France
France generated USD 14 million in 2025 and is expected to reach USD 110 million by 2035. Hospital digital-transformation investment and cancer-screening priorities are supporting adoption beyond a narrow group of academic centers.
Italy
Italy accounted for a 2.6% revenue share in 2025 and is projected to grow at 21.6% CAGR from 2026 to 2035. Academic hospital networks remain the principal adoption base, while variation in regional reimbursement and procurement structures can slow broader scaling.
Spain
Spain generated USD 8 million in 2025 and is expected to reach USD 62 million by 2035. Regional health networks are advancing digital imaging initiatives, and localization requirements can influence supplier selection in decentralized procurement environments.
Netherlands
The Netherlands accounted for a 1.6% revenue share in 2025 and is projected to grow at 23.6% CAGR from 2026 to 2035. A developed healthcare IT environment and coordinated data-governance practices can reduce practical barriers to clinically governed AI deployment.
Asia Pacific Artificial Intelligence in Cancer Diagnostics Market Analysis
Asia Pacific generated USD 84 million in 2025 and is expected to reach USD 820 million by 2035. The region combines substantial cancer-related diagnostic demand with uneven specialist capacity, creating a strong need for scalable imaging, pathology, and remote-access diagnostic support.
China
China generated USD 29 million in 2025 and is expected to reach USD 310 million by 2035. Government-supported healthcare digitalization, large hospital networks, and a broad deployment surface for imaging triage and pathology applications support market development.
Japan
Japan accounted for a 4.7% revenue share in 2025 and is expected to reach USD 142 million by 2035. Demand is reinforced by an aging population, high diagnostic utilization, and clinical interest in earlier detection across major cancer categories.
India
India generated USD 12 million in 2025 and is projected to grow at 28.4% CAGR from 2026 to 2035. Diagnostic capacity gaps in rural and tier-two settings create a compelling use case for cloud-enabled and telemedicine-integrated tools that can extend specialist capabilities.
Australia
Australia accounted for a 2.6% revenue share in 2025 and is expected to reach USD 80 million by 2035. National screening programs and provider efforts to address clinician availability in remote areas are supporting evaluation of AI-assisted diagnostic workflows.
South Korea
South Korea generated USD 10 million in 2025 and is projected to grow at 24.2% CAGR from 2026 to 2035. Advanced health-IT infrastructure and domestic AI-healthcare investment create a favorable environment for both local deployment and regional platform development.
Latin America Artificial Intelligence in Cancer Diagnostics Market Analysis
Latin America accounted for a 4% revenue share in 2025 and is projected to grow at 25.3% CAGR from 2026 to 2035. Adoption is concentrated in larger healthcare markets where private-provider investment and public-system modernization are creating openings for AI-enabled diagnostic tools.
Brazil
Brazil generated USD 8 million in 2025 and is expected to reach USD 83 million by 2035. Multi-site private hospital and diagnostic networks provide an immediate commercial route for suppliers, while regulatory clarity can support broader market entry.
Mexico
Mexico accounted for a 1.3% revenue share in 2025 and is projected to grow at 26.2% CAGR from 2026 to 2035. The market is developing through both private-network adoption and public-sector interest in expanding screening capacity.
Argentina
Argentina generated USD 1.5 million in 2025 and is expected to reach USD 16 million by 2035. Private healthcare providers represent the near-term entry point, although capital-expenditure conditions can influence procurement timing.
Middle East and Africa Artificial Intelligence in Cancer Diagnostics Market Analysis
Middle East and Africa generated USD 15 million in 2025 and is expected to reach USD 133 million by 2035. Demand is concentrated in countries investing in hospital modernization and national health transformation, while lower-resource markets require cost-effective and infrastructure-compatible deployment models.
Saudi Arabia
Saudi Arabia generated USD 5 million in 2025 and is projected to grow at 23.8% CAGR from 2026 to 2035. Healthcare transformation initiatives and investment in oncology, imaging, and digital pathology are supporting adoption across larger provider networks.
UAE
The UAE accounted for a 0.8% revenue share in 2025 and is expected to reach USD 26 million by 2035. Its policy orientation toward AI and digitally enabled healthcare creates an early commercial environment for suppliers seeking Gulf-region reference deployments.
South Africa
South Africa generated USD 3 million in 2025 and is expected to reach USD 24 million by 2035. Private hospital networks offer the most immediate procurement channel, while cloud-hosted diagnostic models may broaden access in constrained public-health environments.
GMI Analyst View
We expect regional performance to remain uneven because the market is governed by different adoption architectures. Mature markets emphasize integration, reimbursement, and clinical governance; rapidly scaling markets prioritize capacity expansion; and earlier-stage markets require solutions aligned with local infrastructure and capital-allocation realities.
Artificial Intelligence in Cancer Diagnostics Market Share & Competitive Landscape
The artificial intelligence in cancer diagnostics market share structure is moderately concentrated at the upper tier, where imaging incumbents, oncology-data platforms, and specialized AI developers compete through different combinations of installed-base access, regulatory capability, clinical validation, and workflow integration. Competitive intensity is rising as buyers favor solutions that can fit enterprise diagnostic environments rather than add separate clinical systems.
GE HealthCare held a 20.0% revenue share in 2025. Its position is supported by AI-enabled imaging capabilities across major modalities and by the ability to embed diagnostic functionality within established provider imaging environments, strengthening its relevance in enterprise procurement decisions.
Siemens Healthineers held a 16.8% revenue share in 2025. The company competes through an integrated imaging and diagnostic-workflow approach, with platform breadth and reporting integration supporting its position among providers seeking fewer technology partners.
Tempus AI held a 16.8% revenue share in 2025. Its multimodal oncology strategy links clinical, genomic, pathology, and real-world data capabilities, positioning the company at the intersection of diagnostic decision support and life-sciences partnerships.
Microsoft participates primarily as an enabling technology provider through cloud infrastructure, AI-development services, and partnerships with health systems and diagnostic-software developers. Its strategic relevance rests on supporting the data, computing, and deployment layers required by third-party diagnostic AI applications.
Flatiron Health, within the Roche ecosystem, brings oncology electronic health record analytics and real-world evidence capabilities to the market. Its differentiated role is strongest where clinical decision support and longitudinal oncology data can inform diagnostic and research workflows.
Paige AI, now integrated within Tempus AI, contributes digital pathology expertise and pathology-focused AI capabilities. The combination strengthens the role of pathology data and foundation-model development in broader oncology diagnostic platform strategies.
PathAI focuses on AI-enabled pathology for pharmaceutical, reference-laboratory, and companion-diagnostics workflows. Its positioning illustrates the importance of specialized clinical evidence and laboratory integration in segments where providers require validated digital pathology infrastructure.
Nanox Imaging targets accessible diagnostic imaging, with relevance in markets where conventional high-capital imaging infrastructure remains constrained. Its approach highlights the opportunity for AI-enabled tools that can support expansion of diagnostic access outside the most established provider settings.
Recent Industry Developments
In May 2026, Tempus AI launched the ArteraAI Prostate Test for metastatic hormone-sensitive prostate cancer. The CLIA-certified, CAP-accredited digital pathology offering is designed to generate individualized risk information from whole-slide pathology images, extending the company's clinical AI portfolio into prostate-cancer prognostic support [5]Tempus AI. "Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use." investors.tempus.com.
In August 2026, Tempus AI announced that its PRISM2 multimodal pathology foundation model demonstrated strong performance across cancer-detection, biomarker-identification, and prognosis-prediction applications in a Nature Medicine study. The development underscores the increasing role of foundation-model architectures in digital pathology and diagnostic AI validation [6]Tempus AI. "Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications." tempus.com.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →